Posted by & filed under Growth & Valuation, Management Issues, Personal Finance.

Description: The new product should help protect against shortages and offer a lower-cost option, the FDA said


Date: Aug 16, 2018


Questions for discussion:

  • Explain the rise in stock price of Teva and fall of Mylan, given no pricing or sales estimates have been released yet for the new product?
  • Do you think competition will actually lower the generic price of the product or will Tevla likely match the current generic price offer to consumers?
  • What would you advise management at both firms?

Leave a Reply

Your email address will not be published. Required fields are marked *